137396-01-1

Basic information

• Product Name: 4-BROMO-3-METHOXYPHENYL PARATOSYLATE
• Synonyms: 4-BROMO-3-METHOXYPHENYL PARATOSYLATE;4-Bromo-3-methoxyphenyl 4-methylbenzenesulfonate
• CAS NO: 137396-01-1
• Molecular Formula: C₁₄H₁₃BrO₄S
• Molecular Weight: 357.22
• Mol File: 137396-01-1.mol

Chemical Properties

• Boiling Point: 462.7°Cat760mmHg
• Flash Point: 233.6°C
• Appearance: /
• Density: 1.491g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.589
• CAS DataBase Reference: 4-BROMO-3-METHOXYPHENYL PARATOSYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-3-METHOXYPHENYL PARATOSYLATE(137396-01-1)
• EPA Substance Registry System: 4-BROMO-3-METHOXYPHENYL PARATOSYLATE(137396-01-1)

Safety Data

• Hazardous Substances Data: 137396-01-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C14H13BrO4S/c1-10-3-6-12(7-4-10)20(16,17)19-11-5-8-13(15)14(9-11)18-2/h3-9H,1-2H3

Upstream product

• 494773-45-4 4-bromo-3-hydroxy-phenyl 4-methyl-benzenesulfonate 
• 74-88-4 methyl iodide 
• 6626-15-9 4-Bromoresorcinol 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1346753-99-8 C₁₂H₁₀F₃NO₄S₂ 
• 1346754-00-4 C₁₁H₁₁NO₂S 
• 1320343-73-4 C₁₇H₂₂BNO₃S 
• 1320343-72-3 C₁₈H₁₇NO₄S₂ 
• 1320343-71-2 C₁₄H₁₅BO₆S 
• 1320343-90-5 C₂₆H₂₄FN₃O 
• 1320343-89-2 C₂₅H₂₄FN₃OS 
• 1320343-88-1 C₂₄H₂₁FN₄O 

Relevant articles and documents

ANTI-PARASITIC COMPOUNDS

Provided are compounds, methods, and pharmaceutical compositions useful for treatment of parasites, e.g., Leishmania. For example, the compound may he represented by Ar—C(=NR1)NR2—A—X—Y—Het2, and pharmaceutically acceptable salts thereof. Ar may be an optionally substituted, aryl or nitrogen-containing heteroaryl. R1 and R2 may independently represent H, optionally substituted C1-C6 alkyl, or optionally substituted C3-C6 cycloalkyl. A may be a bond or an optionally substituted linking moiety comprising 1, 2, or 3 rings. Each ring in the optionally substituted linking moiety may independently be one of: aryl, cycloalkyl, heterocycloalkyl, and heteroaryl. X may be O, S, amide, or a bond. Y may be optionally substituted C1-C14 alkyl or optionally substituted C2-C14 alkenyl. Het2 may be an optionally substituted five-membered nitrogen-containing heteroaromatic ring comprising 1, 2, or 3 ring heteroatoms.

ANTI-FUNGAL TREATMENT

Provided are compounds, methods, and pharmaceutical compositions useful for treatment of fungal infections, e.g., aspergillosis, candidiasis, cryptococcosis, histoplasmosis, and the like. For example, the pharmaceutical composition may include a pharmaceutically acceptable carrier or excipient, and a compound represented by Ar— C(=NR1)NR2— A---X— Y— Het2 and pharmaceutically acceptable salts thereof. Ar may be an optionally substituted aryl or nitrogen- containing heteroaryl. R1 and R2 may independently be H, optionally substituted C1-C6 aikyi, or optionally substituted C3-C6 cyeloalkyi. A may be a bond or an optionally substituted linking moiety comprising 1, 2, or 3 rings. Each ring in the optionally substituted linking moiety may independently be one of: aryl, cyeloalkyi, heterocycloalkyl, and heteroaryl. X may be O, S, amide, or a bond. Y may be optionally substituted C1-C10 alkyi or optionally substituted C2-C10 alkenyl. Het2 may be an optionally substituted five-membered nitrogen-containing heteroaromatic ring comprising 1, 2, or 3 ring heteroatoms.

A highly diastereoselective oxa-Pictet-Spengler approach to (+)-astropaquinone B and (+)-astropaquinone C and the formation of astropaquinone B dimer

A concise and highly diastereoselective synthesis of (+)-astropaquinone B and (+)-astropaquinone C is reported. The synthetic strategy is based on an efficient combination of Doetz benzannulation using a chiral alkyne to construct the naphthalene unit and

5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS

5-membered heteroaryl derivatives of formula (I) or salts thereof, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed.

An enzymatically activated fluorescence probe for targeted tumor imaging

β-Galactosidase is a widely used reporter enzyme, but although several substrates are available for in vitro detection, its application for in vivo optical imaging remains a challenge. To obtain a probe suitable for in vivo use, we modified our previously

An efficient synthesis of coumestrol and coumestans by iodocyclization and Pd-catalyzed intramolecular lactonization

The iodocyclization of acetoxy-containing 2-(1-alkynyl)anisoles and subsequent direct palladium-catalyzed carbonylation/lactonization provide an efficient route to naturally occurring coumestan and coumestrol, and their related analogues.

ERβ ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERβ selectivity

The 2-phenylnaphthalene scaffold was explored as a simplified version of genistein in order to identify ER selective ligands. With the aid of docking studies, positions 1, 4, and 8 of the 2-phenylnaphthalene template were predicted to be the most potentially influential positions to enhance ER selectivity using two different binding orientations. Both orientations have the phenol moiety mimicking the A-ring of genistein. Several compounds predicted to adopt orientations similar to that of genistein when bound to ERβ were observed to have slightly higher ER affinity and selectivity than genistein. The second orientation we exploited, which was different from that of genistein when bound to ERβ, resulted in the discovery of several compounds that had superior ER selectivity and affinity versus genistein. X-ray structures of two ER selective compounds (i.e., 15 and 47) confirmed the alternate binding mode and suggested that substituents at positions 1 and 8 were responsible for inducing selectivity. One compound (i.e., 47, WAY-202196) was further examined and found to be effective in two models of inflammation, suggesting that targeting ER may be therapeutically useful in treating certain chronic inflammatory diseases.

Total syntheses of three natural products, vignafuran, 2-(4-hydroxy-2-methoxyphenyl)-6-methoxybenzofuran-3-carboxylic acid methyl ester, and coumestrol from a common starting material

Vignafuran 2, 2-(4-hydroxy-2-methoxyphenyl)-6-methoxybenzofuran-3-carboxylic acid methyl ester 3, and coumestrol 4 were efficiently synthesized from the same starting material, 4-bromoresorcinol 14a, through the common intermediate, diarylacetylene 7. The key steps of these syntheses were the tetrabutylammonium fluoride (TBAF)-catalyzed benzo[b]furan ring formation for 2 and the carbonylative ring closure methodology catalyzed by a Pd complex for 3 and 4. The Royal Society of Chemistry 2000.

Substrate regulation of product distribution in the reactions of aryl chromium carbene complexes with alkynes

The reactions of arylcarbene complexes with alkynes were examined for six of the nine possible substitution patterns for mono- and dioxygenated aryl substituents of the carbene carbon. The product distributions were found to be highly dependent on a numbe